2013 ALA Midwinter Meeting – Arthur Curley Lecturer Lisa Genova – Video


2013 ALA Midwinter Meeting - Arthur Curley Lecturer Lisa Genova
American Libraries #39; George M. Eberhart interviews novelist and neuroscientist Lisa Genova, who presented the 2013 Arthur Curley Memorial Lecture. Genova uses her expertise and research in the brain to write detailed portrayals of characters with neurological conditions, including autism and early-onset Alzheimer #39;s. In this video she talks about her research, as well as how libraries are uniquely positioned to serve children with autism, her unexpected role as advocate, and the books that inspired her interest in neuroscience. See, hear, and read more about what #39;s going on at Midwinter mdash;in real time and after. American Libraries Coverage: americanlibrariesmagazine.org Twitter: @alamw and #alamw13 Facebook: http://www.facebook.com Flickr: http://www.flickr.com Pinterest: pinterest.com

By: AmLibraryAssociation

Visit link:
2013 ALA Midwinter Meeting - Arthur Curley Lecturer Lisa Genova - Video

On Strengthening the Longevity Research Community

Building scientific communities with strong ties to the broader public runs in just the same way as building any community in this day and age - which means very differently to the way things used to be. The internet, open data, and cheap global communication allow a whole new layer of activism and effort by small groups of researchers to stand beside the traditional conferences, funding sources, and institutional relationships. The successful research community of today will be a lot more in touch with the public who stand to benefit from its work, and with the advocates and activists who support progress in the field. You might look at calorie restriction research as an example of strong ties between researchers and advocates, leading to a greater number of human research programs and a greater visibility for calorie restriction as a lifestyle choice. Similarly for aging research: efforts like the Methuselah Foundation and SENS Research Foundation have emerged as much from visionaries and support outside the research community as from the work of those within.

It may be easier to build communities these days, but that doesn't mean it's easy. Effort is definitely involved, along with some measure of fortuitous happenstance, the upkeep of watering holes and initiatives, a need for strong personalities to make and maintain diverse connections, the creation of collaboration tools and outreach programs. The list goes on.

Some of the folk at the International Longevity Alliance are enthused by the idea of building more and better threads to link and strengthen the longevity science community. From their point of view there is much yet to be done in terms of opening up collaboration between research groups and between researchers and interested members of the public. For the moment their efforts center around the Denigma resource database:

When I started research 12 years ago, articles were on paper or from books borrowed at the library in whatever language, and contacting researchers was done through letters sent by mail - needless to say the pace of research was much slower then. The Internet and the area of computerized experimental data is changing everything. PubMed is the new bible and collaborations *can* go at the speed of emails. *Can*, because there is still much that can be done to go even faster:

Research labs generally remain local and closed places that do not interact much with other ones, even if it were beneficial for both. In many cases this a matter of distance and not knowing each other, which some summarize as follows:"science improves at the rate of congresses".

Citizen science is a burgeoning new revolution: Imagine what could happen if a large part of the longevity alliance (currently about 5,000 members) was attending lab meetings and helping in one way or another... For example statistics, experiment design, grant or paper writing, or basic administration (another break for research...)

Luckily we are not the first ones to try to optimise and systematize research, in biogerontology in particular: pioneers have created important bricks for the grand edifice. We have the ingredients and now we need to create a recipe to be adopted by aging research This was clearly highlighted at the Eurosymposium on Healthy Ageing (EHA2012, organised by Heales in Brussels, and where various members of the International Longevity Alliance met). The need for a centralized place for collaboration against aging was strongly raised and a few days later emails were springing on the matter, with names like "Collaborative Resource for Gerontology" (by Georg Fullen, who presented Denigma at EHA2012) or "inSilicoSENS" (by Aubrey de Grey, where SENS = Strategies to Engineer Negligible Senescence).

There is a fair amount of this sort of sentiment in the broader research community these days: towards open publishing, greater transparency, relationships established with philanthropists and supporters in the public. It is the mood of the times, enabled by the falling cost of communication and the increasing capacity of the internet. But mood of the times or not, it still takes people to do the work, bang the drum, build the tools.

Source:
http://www.fightaging.org/archives/2013/01/on-strengthening-the-longevity-research-community.php

But What About Pushkin?

From the Russian end of the longevity advocacy community:

A man strives for justice, but the most unjust thing in life is the inevitability of death. Here's a small child, then an adult, he learns, grows up, falls in love, gets married - divorce, have children, he is happy and suffering, dreaming and disappointed, laughing and crying, running, resting, but for all that the fate is death, imminent death due to aging. Monstrous injustice! A man with his life does not deserve death. People put up with this situation, they talk about natural dying, saying that a person must make room. These excuses have the sound of death due to frustration, due to a lack of knowledge about the theoretical possibilities of science, not a desire to act rationally. A person finds it easier to accept death and aging than to begin to act.

So the struggle with death and aging: a complex internal decision, the decision to confront the established foundations, the victory of reason over faith and the desire for psychological comfort, the victory over short-term interest. In 20 years it will not matter exactly what you ate today, what color your wallpaper, and where you go to relax - only one thing will be important, how you confronted death in our day. And in a hundred years, nothing that you are or do now will be important if aging is not defeated.

"But what about Pushkin? Everyone remembers him!" - Pushkin would love to change places with you, as he is dead while you are alive and can act. The memory of a man is not the man himself. The good works of Pushkin do not help him in any way nor are a compensation for his dying. Conversely, a victory over aging grants a continuation and the opportunity to do many things. Transhumanism is the desire for freedom. Freedom is possibility. Pain, suffering and aging limit our possibilities. Death reduces them to zero. Improving people via the new nano-, bio-, info-technology of the 21st century offers opportunities only dreamed of by philosophers of the past. It is important to take action.

Link: http://translate.google.com/translate?hl=en&sl=auto&tl=en&u=http://m-batin.livejournal.com/154691.html

Source:
http://www.fightaging.org/archives/2013/01/but-what-about-pushkin.php

Considering Cybernetic Immortality

If the 2045 initiative continues onwards as the founder intends, we're all going to be hearing more about what here is called "cybernetic immortality" - copying the data of the mind to run in machinery that is much more robust and longer-lasting than its biological equivalent. I consider the popularity of this goal (as put forward by Ray Kurzweil, for example) something of an existential threat, insofar as it may drain enthusiasm and allies from work on rejuvenation biotechnology now, and in future decades it may become cheaper to build mind-copies than to finalize the means to reverse and prevent aging in our biological bodies. You don't need to fully understand the brain to copy it given powerful enough computers and scanning tools, and you don't need to understand aging much better than we do today to create rejuvenation biotechnology.

There are more than enough people in the world who consider a copy of themselves a suitable continuation to support this sort of technology in preference over medicine for rejuvenation. Today a person can choose to support programs like SENS research on the rejuvenation side or the 2045 group on the mind copying side - it's not just talk, it's a rather important choice between aiming for continued survival of the self or aiming for death while a copy of you survives.

Cybernetic immortality - fantasy or scientific problem? I can answer that right away. It is a scientific problem - of approximately the same type as the problem of people going into outer space, which was proposed by Tsiolkovsky at the turn of the 20th century. Why, despite the support of important scientists (such as V. Turchin, C. Joslyn, R. Kurzweil, A. Bolonkin, B. Bainbridge and others), is this idea rejected by many, or at best treated with skepticism?

There are many reasons for this. Firstly: the scale of this super-project, which really does verge on fantasy, is too "overwhelming", for the "average" scientific mindset, which is mundane and cautious, and too dependent on the opinion of the scientific management. Anything is proposed nowadays if financing can be secured for it. I'm not even talking about the colossal growth of false science - charlatans, mages, "miracle-workers". All of this throws a shadow on the idea of cybernetic immortality.

Furthermore, we are now only at the approach stage of a solution to this problem, specific steps for its development are in many ways only at discussion level, and creative solutions are required. The eternal idea of immortality has been expressed in myths, legends and religious beliefs. Hence the prejudice that it is not compatible with science.

What is the basis for the conviction that the problem of cybernetic immortality is a real scientific problem? It does not contradict the principles of science. In fact, it finds a theoretical basis in them - above all, in the fundamental principle of the iso-functionalism of systems, which essentially heralded the beginning of the computer era. The idea of this principle is that the same complex of functions may be reproduced on substrates with different physical properties. Hence the fundamental possibility to reproduce the functions of a living system and the brain on non-biological substrates, which also fully applies to mental functions.

Link: http://hplusmagazine.com/2013/01/21/d-i-dubrovsky-cybernetic-immortality-fantasy-or-scientific-problem/

Source:
http://www.fightaging.org/archives/2013/01/considering-cybernetic-immortality.php

Natural Death: We Should be Worried About It

Edge magazine recently ran their yearly question, which this year is "what should we be worried about?" There are more than a hundred and fifty responses from various authors and folk in the public eye, and I'll confess to not having read more than a handful - time is ever fleeting, and none of us have enough of it between dawn and dusk. Thus while I noticed Aubrey de Grey's response, I missed seeing this rather better one. You should definitely read the whole thing, not just the concluding except below:

What Should We Be Worried About: Natural Death

Even if the probability of quickly finding a technological method to delay or reverse senescence is low, we have been devoting far too little effort to it. After all, no matter what else we might achieve with our work in life, we soon won't be around to enjoy it. There are other problems on the planet to worry about, but none more personally important. And yet, despite this motivation, there is very little money being spent on longevity research. Because there is no history of success, and because of widely held religious beliefs, government won't fund it. And because achieving success will be difficult, and the marketplace is flooded with false claims, industry has little interest in solving the problem. Although the profit could be astronomical, there is no easy path to attain it, unlike for cosmetic improvements. Over a hundred times more money is spent on R&D for curing baldness than for curing aging. We may someday find ourselves with extended lifespans as an unintended side effect of taking a pill that gives us fuller hair.

This absurd situation is typical for high-risk, high-reward research in an area without an established record of success. Even with strong motivation, financial support is nearly nonexistent. Scientists working on life extension often lack for equipment or a livable salary, and risk their careers by conducting oddball research that repeatedly fails. The problems are hard. But even with limited resources, a handful of scientists are devoting their lives to the pursuit, because of what's at stake. Success will require research on a similar scale as the Manhattan Project, but government and industry won't be supporting it. The greatest hope is that private individuals will step forward and fund the research directly, or through organizations established for that purpose. Maybe an eccentric, farsighted billionaire will want a chance at not dying. Or maybe many people will contribute small amounts to make it happen. This is being done, to some extent, and it gives me hope.

Personally, I know I am not so different than other people. I also have a very difficult time accepting mortality. When I think about all who have and will be lost, and my own impending nonexistence, it makes me ill. It's entirely possible that the hope I have for a technological solution to aging and death is biased by my own aversion to the abyss. Being realistic, given our current rate of technological advance, although I'm hopeful that radical life extension will happen before I die, I think it's more likely that I'll just miss it. Either way, whether aging is cured within my lifetime or afterwards, it won't happen soon enough. Good people are suffering and dying, and that needs to change in a way that's never been done before.

The more people who set out to propagate this message with style and flair, the better all our chances become. Money is the root obstacle, a lack of funding for rejuvenation research based on the SENS vision that is well planned but moving slowly - but persuasion can move money to where it is needed. You just need enough of it.

Source:
http://www.fightaging.org/archives/2013/01/natural-death-we-should-be-worried-about-it.php

On Long-Lived Cancer-Resistant Rodents

An open access review paper looks at the rise of mole-rats in cancer and aging research:

Most rodents are small and short-lived, but several lineages have independently evolved long lifespans without a concomitant increase in body-mass. Most notable are the two subterranean species naked mole rat (NMR) and blind mole rat (BMR) which have maximum lifespans of 32 and 21 years, respectively. The longevity of these species has sparked interest in the tumor suppression strategies that may have also evolved, because for many rodent species (including mice, rats, guinea pigs, gerbils, and hamsters) tumors are a major source of late-life mortality.

Here, we review the recent literature on anti-cancer mechanisms in long-lived rodents. Both NMR and BMR seem to have developed tumor defenses that rely on extra-cellular signals. However, while the NMR relies on a form of contact inhibition to suppress growth, the BMR evolved a mechanism mediated by the release of interferon, and rapid necrotic cell death. Although both organisms ultimately rely on canonical downstream tumor suppressors (pRB and p53) the studies reveal species can evolve different strategies to achieve tumor-resistance. Importantly, studies of these cancer-resistant rodents may benefit human health if such mechanisms can be activated in human cells.

Link: http://www.frontiersin.org/Genetics_of_Aging/10.3389/fgene.2012.00319/full

Source:
http://www.fightaging.org/archives/2013/01/on-long-lived-cancer-resistant-rodents.php

Protection of genetic heritage in the era of cloning

Research on human beings has expanded greatly due to progress and the evolution of society as well as customs. Not only the unceasing development of research on human beings, but also interference in the beginning and end of life with homologous and heterogonous human reproduction, surrogate motherhood, cloning, gene therapies, eugenics,euthanasia, dysthanasia, orthothanasia, assisted suicide, genetic engineering, reassignment surgery in cases of transsexuality, the use of recombinant DNA technology and embryonic stem cells, transplantation of human organs and tissues, biotechnology and many other scientific advances. Scientific progress goes faster than the real needs of human beings, who are the final recipient of the entire evolutionary progress. Hence, there is the need to scrutinize w...

MedWorm Sponsor Message: Find the best Christmas presents and January Sales in the UK with this simple shopping directory.

Source:
http://www.medworm.com/index.php?rid=6986259&cid=c_449_19_f&fid=37449&url=http%3A%2F%2Fwww.scielo.br%2Fscielo.php%3Fscript%3Dsci_arttext%26pid%3DS1516-84842012000600016%26lng%3Den%26nrm%3Diso%26tlng%3Den

Stem Cell Agency Adds Fresh Details to IOM Response

The California stem cell agency today
issued a press release touting “dramatic changes” at the agency in response to critical recommendations by the Institute of Medicine.

The press release contained a few more
details about the changes than were released in the Power Point
presentation yesterday. Here is the text of those details.
  • “The 13 Board members appointed from
    institutions eligible for funding from the stem cell agency, such as
    those in the University of California system, would no longer vote on
    any grants brought before the Board but would instead abstain
  • “All members of the Board would
    be able to participate in discussions on applications but only
    patient advocates and independent members of the Board would be able
    to vote on funding issues (members would continue to refrain from
    any discussion of specific applications from their institutions)
  • “Patient Advocates would
    continue to be members of the Grants Working Groups but would not
    vote on individual applications
  • “Programmatic review, aimed at
    balancing the agency’s portfolio, would take place at public Board
    meetings where members have a chance to make changes to
    recommendations from the Grants Working Group
  • “Industry involvement would
    increase, where appropriate, on the Grants Working Group, and also
    feature in a newly constituted Scientific Advisory Board; the
    structure and membership of this group is still under discussion
  • “Appeals on applications not
    recommended for funding will be handled by science staff who will
    evaluate them, determine if they merit further review by the Grants
    Working Group, and ultimately make recommendations to the Board.
    Staff will also be allowed to advocate for additional grants not
    recommended for funding by the Grants Working Group that they
    believe should be considered in programmatic review
  • “The Chair and President would
    share a division of responsibilities with the President supervising
    all scientific operations and internal operational responsibilities.
    In addition the Chief Financial Officer would report to the
    President. The Chair would handle the ‘external affairs’ aspect
    of the agency, things such as financial sustainability to raise
    additional funds, state legislative relations, bond financing,
    public communications etc.
  • “IOM recommendation on the
    creation of a Scientific Advisory Board to provide counsel on such
    issues as funding priorities and portfolio strategy will be
    implemented by staff
  • “IOM recommendations on
    Intellectual Property will be referred to the agency’s IP
    subcommittee which will review and report back to the full board
    with options and recommendations
  • “IOM recommendations on
    Sustainability: Chair, working with the President, will develop a
    plan to address this and present to the Board when ready

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/MHSytXHG-zU/stem-cell-agency-adds-fresh-details-to.html

California Stem Cell Agency to Pitch Newspaper Editorial Boards

The California stem cell agency is
planning an editorial road show with major California newspapers to
explain its new plan to deal with the recommendations of the
Institute of Medicine(IOM) for major changes at the agency.

In what might be called the kickoff to the campaign, the agency this afternoon issued a press release hailing the plan as making “dramatic changes.”

The agency could have a tough audience.
The newspapers editorializing on the subject were unanimously in
favor of the IOM recommendations. One said the agency needs to clean
up its act. They warned of a loss of public trust along with losing the
possibility of continued financial support. (For a sample, see here
and here.)

CIRM Chairman J.T. Thomas said during
today's meeting that a public relations foray was in the works
following board action on his proposals yesterday. He said,

“The opportunity is ripe.”

His comments came after CIRM Director
Jeff Sheehy, a UCSF communications manager, urged engaging the
editorial boards.
Thomas' plan meets only a portion of
the IOM recommendations and sidestepped a call for
creating a new majority on the board of independent members. The IOM
said “far too many” board members – at least 13 – are tied to
institutions that receive money from CIRM. Thomas' plan would have
the 13 voluntarily restrain from voting on any grants for any
institution.
A compilation by the California Stem
Cell Report
shows that roughly 90 percent of the $1.7 billion awarded
by directors has gone to institutions with links to the directors.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/sN7GVoQPGjA/california-stem-cell-agency-to-pitch.html

Nature on the IOM and the California Stem Cell Agency

The journal Nature today said on its
web site that the California stem cell agency plans to make a “few
changes” in response to a critical report from the Institute of
Medicine(IOM).

A short piece by Monya Baker on the agency's response yesterday summarized
some of the IOM recommendations and the CIRM response. Baker wrote,
She said,

"Other IOM recommendations were only
indirectly addressed by (CIRM Chairman J.T.) Thomas’ plan. The IOM report had stated
that the board should restrict itself to an 'oversight' role
rather than an 'operational' role. Thomas’s recommendations
instead described ways to avoid overlapping duties. His own role as
chair is to handle 'external affairs' whereas CIRM’s president
will be to handle scientific and internal affairs."

Baker also carried the favorable
comments from John M. Simpson of Consumer Watchdog.   

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/JU2zXAO4Q1Q/nature-on-iom-and-california-stem-cell.html

Roll Call Vote on the Thomas Plan Dealing with IOM Recommendations

Here is the roll call vote yesterday on the plan to deal with the findings of the Institute of Medicine
concerning the California stem cell agency. The vote was 23-0 with
one abstention. The board has 29 seats. Not all board members were in attendance,
and it is not entirely clear whether all the board members in attendance
voted. Among other things, the plan calls for members with links to
institutions that could benefit from CIRM awards to voluntarily refrain from
voting on any applications for funding – not just those to their
institutions. The roll call was provided by a spokesman for the
agency.

Yes votes
David Brenner, dean of the UC San
Diego medical school.
Anne Marie Duliege , vice president of
Affymax
Michael Freidman, CEO City of Hope
Michael Goldberg, executive chairman of Nodality, Inc., and DNAnexus, appointed as executive officer of a commercial life science entity
Sam Hawgood, dean of the UC San
Francisco medical school
Steve Juelsgaard, former executive
vice president of Genentech, appointed as executive officer of a
commercial life science entity
Sherry Lansing, chairwoman of the UC
board of regents, appointed as patient advocate
Jacob Levin, assistant vice
chancellor, research, UC Irvine, and alternate for Sue Bryant,
interim provost at UC Irvine
Bert Lubin, CEO of Childrens Hospital,
Oakland
Robert Price, associate vice
chancellor for research, political science professor, alternate for
the UC Berkeley chancellor
Francisco Prieto, Sacramento physician
and patient advocate member of the board
Robert Quint, San Jose physician and
patient advocate member
Duane Roth, San Diego businessman,
appointed as executive officer of a commercial life science entity
Joan Samuelson, patient advocate member
Jeff Sheehy, patient advocate member
Jon Shestack, patient advocate member
Os Steward, patient advocate member and
head of the Reeve-Irvine Research Center at UC Irvine
Jonathan Thomas, chairman of the board
and Los Angeles bond financier
Art Torres, patient advocate member
Kristiina Vuori, interim CEO of
Sanford Burnham Research Institute
Diane Winokur, patient advocate member

Claire Pomeroy, dean of the UC Davis medical school
Shlomo Melmed, senior vice president for academic affairs, Cedars Sinai
Abstaining
Michael Marletta, CEO of Scripps
Research

(Editor's note: Based on information provided by CIRM, an earlier version of this item incorrectly reported that the vote was 21-0. It also contained errors on three names. All have been corrected. Thanks for the heads up on the misspellings from a board member who will remain unnamed.)

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/DYyBzk0Er5g/roll-call-vote-on-thomas-plan-dealing.html

Meager, Meager Coverage of Yesterday's IOM-Stem Cell Meeting

The $3 billion California stem cell
agency seemed all but invisible this morning in terms of mainstream
media coverage.

Only one major outlet reported on
the watershed events yesterday at the CIRM governing board meeting at
the Claremont Hotel in Oakland – at least from what our Internet
searches show.
The piece was written by Bradley Fikes
in the San Diego U-T, the dominant daily newspaper in that area,
which is a major biotech center. The major media in the San Francisco
Bay area, home to the stem cell agency and also a biotech center, were absent from the coverage.
Fikes wrote a straight forward account
of the meeting, saying that the governing board voted “ to
accept in concept proposed
changes
 to reduce conflicts of interest on the agency's
governing committee.”
Fikes wrote the story based on the audiocast of the meeting. He probably would not have written his daily piece without the availability of the audiocast. 
Some of those connected with the stem
cell agency often wonder about the lack of mainstream coverage of its doings,
particularly the lack of favorable coverage.
Much of it has to do with the shriveled
state of the media business, which is understaffed and overworked
compared to 15 years ago. Specialized science reporters are all but
an extinct species. Also, the mainstream media has traditionally
ignored the affairs of most state agencies.
Speaking as a former editor at a major
Northern California newspaper, I would not have sent a reporter to
cover this week's two-day CIRM board meetings. It would have consumed
too much valuable time with little likelihood of a major story,
especially when weighed against other story possibilities. There was
no guarantee that the board would have even acted. The events and
their significance could be better handled in a roundup story later
with more perspective, perhaps keying on the board's meeting in
March, where details of yesterday's action will be fleshed out. The
fact is that many, very important events occur within state
government every day that never receive media attention. Some don't
even see the light of day until a catastrophe occurs.
All of this may be deplorable in the
eyes in stem cell agency backers and others, but it is the reality of
today's news business.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/8q4FDQb-BUk/meager-meager-coverage-of-yesterdays.html

Reaction to IOM: California Stem Cell Directors Approve Plan on Conflicts of Interest and More

Directors of the $3 billion California
stem cell agency today approved a far-reaching plan aimed at resolving long-standing
conflict of interest issues involving the agency's governing board
and also at helping to maintain credibility with the public.

Jonathan Thomas
CIRM photo
The framework of the proposal by CIRM
Chairman J.T. Thomas moved forward on a 23-0 vote with one
abstention. He laid out the plan in response to sweeping recommendations from a blue-ribbon study by the Institute of Medicine. Details will be worked out and come back to the board in March. 
Acknowledging that many board members
were not pleased with the IOM criticism of the agency, Thomas said, 

“This is one of those times that we must move forward and compromise.” 

He
said issues such conflicts of interest have “stolen focus” from
the good scientific work that the agency has funded.
Thomas was reacting to the $700,000 IOM
study commissioned by CIRM governing board. The IOM recommendations
called for removing conflict
of interest problems, cleaning up a troubling dual-executive arrangement
and fundamentally changing the nature of the governing board. The IOM proposals would strip the board of its ability to approve individual grants,
greatly strengthen the role of the agency's president, significantly
alter the role of patient advocates on the governing board and engage
the biotech industry more vigorously.
Thomas' plan, which would be put in
place for up to a one-year trial period, would not do all that the
IOM wanted, but would move strongly in that direction.
State Controller John Chiang, chairman
of the only state entity with financial oversight over CIRM, endorsed
most of the proposal, said deputy controller Ruth Holton-Hodson. She
told CIRM directors that Thomas' plan was thoughtful and positive,
although Chiang did not support continued involvement of the chairman
in day-to-day operations.
The Thomas plan, which would not require legislative approval, would:
  • Have 13 members of the 29-member board
    refrain from voting on specific grant applications. The 13 would be from institutions that could benefit from CIRM grants. They would be
    allowed to participate in discussions. Thomas said this would deal
    with financial conflict of interest questions. 
  • Increase industry participation of
    industry in grant application review and step up business involvement
    internally at CIRM, including development of RFAs.
  • Redirect all scientific appeals to
    staff to evaluate for possible re-review before they go to the full
    board.
  • Move “programmatic” review of
    grants to public sessions of the full board instead of being held
    behind closed doors during grant review sessions. Patient advocate
    directors now sitting on the grant review group would no longer be
    allowed to vote during the closed-door review sessions, but they
    could participate in the discussion.

It appears, however, that the Thomas
plan would do little to deal with the dual-executive problems identified
by the IOM.

Consumer Watchdog's John M. Simpson, a
long observer of the stem cell agency, welcomed the response by
CIRM. Writing on his blog, Simpson said,

 "It looks like
the message is finally getting through to California's stem cell
agency board....
Part of what is driving the new
approach is the realization that CIRM will need to find a new source
of funding -- possibly going back to the voters -- if it is to
continue.  As Thomas told the board today, 'If we don't
have credibility, we won't have a chance of sustaining the agency.'"

During the lengthy debate this
afternoon, one director after another said they did not agree with
all that the IOM had to say, but said maintaining credibility and
trust was the key to the sustainability of the organization.
CIRM will run out of money for new
grants in less than four years. Thomas said he is working on a plan
to continue the agency's effort into the future. Details of that will
be disclosed later, he said.

(Editor's note: An earlier version of this item, based on incorrect information from CIRM, said the vote was 21-0. The correct figure is 23-0.)

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/Phybdqb0SV0/iom-california-stem-cell-directors.html

Meager, Meager Coverage of Yesterday’s IOM-Stem Cell Meeting

The $3 billion California stem cell
agency seemed all but invisible this morning in terms of mainstream
media coverage.

Only one major outlet reported on
the watershed events yesterday at the CIRM governing board meeting at
the Claremont Hotel in Oakland – at least from what our Internet
searches show.
The piece was written by Bradley Fikes
in the San Diego U-T, the dominant daily newspaper in that area,
which is a major biotech center. The major media in the San Francisco
Bay area, home to the stem cell agency and also a biotech center, were absent from the coverage.
Fikes wrote a straight forward account
of the meeting, saying that the governing board voted “ to
accept in concept proposed
changes
 to reduce conflicts of interest on the agency's
governing committee.”
Fikes wrote the story based on the audiocast of the meeting. He probably would not have written his daily piece without the availability of the audiocast. 
Some of those connected with the stem
cell agency often wonder about the lack of mainstream coverage of its doings,
particularly the lack of favorable coverage.
Much of it has to do with the shriveled
state of the media business, which is understaffed and overworked
compared to 15 years ago. Specialized science reporters are all but
an extinct species. Also, the mainstream media has traditionally
ignored the affairs of most state agencies.
Speaking as a former editor at a major
Northern California newspaper, I would not have sent a reporter to
cover this week's two-day CIRM board meetings. It would have consumed
too much valuable time with little likelihood of a major story,
especially when weighed against other story possibilities. There was
no guarantee that the board would have even acted. The events and
their significance could be better handled in a roundup story later
with more perspective, perhaps keying on the board's meeting in
March, where details of yesterday's action will be fleshed out. The
fact is that many, very important events occur within state
government every day that never receive media attention. Some don't
even see the light of day until a catastrophe occurs.
All of this may be deplorable in the
eyes in stem cell agency backers and others, but it is the reality of
today's news business.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/8q4FDQb-BUk/meager-meager-coverage-of-yesterdays.html

Transfer Students in Science Majors: Would you like to talk about your transfer experience at the university?

This is a research project about transfer students from a community college; I am asking students about their transfer experience to the university.

To participate, the requirements are: 1) You are a prior community college student who completed either an AGEC or an Associate of Science at a community college. 2) You are enrolled in a Science major at the UA. 3) You must have completed at least ONE semester (with graded units) at the UA. 4) You must be over 18 years old.

Participation consists of an interview of about ten questions about your college transfer experience, and completing a short survey. The interview is designed to take about 30 minutes, and can be done on campus at a time and location convenient for you during January and February 2013.

You will be compensated for your participation at the time of the interview.

If you are at all interested in participating, please reply to Ruthann at rtcoyote@email.arizona.edu or call me at (520) 256-0441 immediately. Replying does not fully commit you; it simply indicates your interest. I anticipate that possibly more students will want to participate than I will be able to accommodate, so interviews will be scheduled on a first-come, first-serve basis.

An Institutional Review Board responsible for human subjects research at The University of Arizona reviewed this research project and found it to be acceptable, according to applicable state and federal regulations and University policies designed to protect the rights and welfare of participants in research.

Thank you so much for considering being part of this research!

Source:
http://physiologynews.blogspot.com/2013/01/transfer-students-in-science-majors.html

Undergraduate Research Opportunities Consortium (UROC).

UROC is a partnership of several University of Arizona undergraduate research programs, led by the Graduate College, which primarily focus on STEM fields. UROC offers a wide range of 10 week summer undergraduate research opportunities to help undergraduates prepare for graduate school. UROC connects students to meaningful research projects, faculty mentors, and a cohort of like-minded students whose goal is to pursue master’s and PhD degrees. Additionally, students will receive intensive, personalized preparation for the graduate admission process, including workshops to prepare for the GRE.

Important Dates

UROC Starts June 2, 2013 and ends August 7, 2013

Apply by February 1

Note: Letters of recommendation are not required.

Benefits

· Research project

· Faculty mentor

· Workshops/preparation for graduate admission process (personal statements, presentation skills, funding, GRE)

· Speaker series

· Social opportunities and a support network

· Financial support (pay, stipends)

· Upper division academic credit

· On-campus housing available

· Poster session, oral presentation, and closing ceremony

Each of the UROC programs differs in their selection criteria. Visit the UROC web site for more information about individual programs.

Learn more! Here’s how to focus the search—

For biological science majors:

· Minority Health Disparities

· Minority Access to Research Careers

For environment-related majors:

· Biosphere 2 REU

For physical science majors:

· Hooked on Photonics REU

· Integrated Optics for Undergraduates REU

For all majors:

· Summer Research Institute

Questions?

Contact Stephanie Adamson at 520-626-0095 or send email to UROC@grad.arizona.eduSource:
http://physiologynews.blogspot.com/2013/01/undergraduate-research-opportunities.html

Justified Round Table: "Truth and Consequences"

Raylan got duped and Boyd called out a duper on the latest episode of Justified Season 4.

How does our Round Table team of Jim Garner, Carla Day and Nick McHatton feel about "Truth and Consequences?" Read on for their Q&A and then chime in with your own answers below...

-------------------------------------------

What was your favorite scene from "Truth and Consequences?"
Nick: Raylan's skepticism of Eve's "abilities."

Jim: I loved Art, Rachel and Raylan in Art's office. Both Rachel and Art took some good-natured digs at Raylan with some great humor mixed into it.

Carla: I'm going to be a rebel and go with my least favorite best scene -- the snake attack. That was horrific to watch, but at least it wasn't gratuitous. It served an important purpose and lead to an amazing snake off.

Justified RT Logo

Should Boyd have done more to stop Billy from picking up the Rattlesnake?
Nick: I thought Boyd genuinely attempted to stop Billy in the beginning, but Billy tried to blindly follow his faith in God and got bit.

Jim: Boyd did as much as he could, short of carrying the anti-venom on him. He stopped him physically and tried to warn him that his pride was running away with him.

Carla: The truly best option would have been for Boyd to take have taken his box and gone home, but this is Boyd. For him, he went out of his way to try to convince Billy not to handle the snake. That was mighty righteous of him. It ended up being a game of chicken with a snake rather than with cars and Cassie/Billy lost.

When Boyd revealed to the congregation that Cassie milked the snakes, did he expose a con in the works or just destroy some people's faith?
Nick: He did both because they go hand in hand. Cassie's milking of the venom (and Billy not knowing) is part of her con to gain followers in the church, and if the main showing is a fraud then some are going to lose faith.

Jim: Boyd revealed Cassie's manipulation for his own reasons, but an argument can be said that he was protecting the people of Harlan County. Sadly the truth may have had the side effect of damaging some people's faith. I suspect we will see Ellie May back at work soon.

Carla: I suspect both, but we won't really know how people react until they either show back up at the tent or not the next day.

Did Lindsey and her ex Raylan or should Raylan be worried that Lindsey is missing and could be in trouble?
Nick: It's hard to say since they both come from a con background, but I'm personally leaning towards both of them cleaning out Raylan and moving on. Either way it felt like she ran her course, so I'm happy she's gone.

Jim: I find it hard to believe that Lindsey would have been as honest about her previous law infractions with Raylan if she was planning on robbing him blind. I suspect that if she did go with her ex-husband it wasn't by choice.

Carla: I agree with Jim that Lindsey probably didn't go entirely on her own. However this is resolved though, I hope she's out of Raylan's life. Not a fan.

Should Raylan have been more sympathetic to Rachel leaving her husband?
Nick: Raylan was being Raylan with her, so no.

Jim: Raylan has been dealing with his own marriage having fallen apart and that his ex-wife is now pregnant with his child. If anyone could have been sympathetic, it would have been him. I guess he really is a "redneck" at heart and doesn't want to talk about feelings.

Carla: He's Raylan. He doesn't have feelings or empathy.

Source:
http://www.tvfanatic.com/2013/01/justified-round-table-truth-and-consequences/

The Vampire Diaries Sneak Peek: You Creeping Tom!

Note to Kol: You really might wanna make a run for it.

At the conclusion of this week's Vampire Diaries, Elena decided that her brother ought to kill this Original in order to de-compel Damon and also complete Jeremy's hunter mark.

Now, based on the following clip from next Thursday's "A View to A Kill," we also see that Klaus has plans to stake his sibling once and for all. Is Rebekah on board? What is Klaus' reaction to finding a certain someone in her bedroom? And is Kol's time in this world coming to an end?

Watch the latest sneak peek now - and don't forget to visit our Vampire Diaries music section, updated after each new episode!

Source:
http://www.tvfanatic.com/2013/01/the-vampire-diaries-sneak-peek-you-creeping-tom/